AN2 Therapeutics, Inc (ANTX) insider trading
Every open-market stock purchase and sale by AN2 Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders sold $55.3K over the last 12 months (8 sales). No open-market buys.
- Last insider buy: Eric Easom (CEO), $10.7K, 16 months ago.
Last 12 months: insiders bought $0 (0 buys) and sold $55.3K (8 sales). Last close $3.82 on Jun 4, 2026.
Recent ANTX insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| May 29, 2026 | Sarah Joanne Williams (Insider) | Sold | $1.2K |
| Apr 10, 2026 | Gilbert Lynn Marks (Insider) | Bought (not open market) | — |
| Apr 10, 2026 | Patricia A. Martin (Insider) | Bought (not open market) | — |
| Apr 10, 2026 | Kabeer Aziz (Insider) | Bought (not open market) | — |
| Mar 19, 2026 | Eric Easom (CEO) | Sold (not open market) | $3.9M |
| Mar 19, 2026 | Eric Easom (CEO) | Sold (not open market) | $3.2M |
| Mar 19, 2026 | Eric Easom (CEO) | Sold (not open market) | $1.6M |
| Mar 19, 2026 | Joshua M Eizen (Insider) | Sold (not open market) | $1.6M |
| Mar 19, 2026 | Lucy Day (CFO) | Sold (not open market) | $1.2M |
| Mar 19, 2026 | Sanjay Chanda (C-suite exec) | Sold (not open market) | $1.1M |
| Mar 19, 2026 | Lucy Day (CFO) | Sold (not open market) | $1.1M |
| Mar 19, 2026 | Eric Easom (CEO) | Bought (not open market) | $1M |
| Mar 19, 2026 | Eric Easom (CEO) | Bought (not open market) | $977K |
| Mar 19, 2026 | Eric Easom (CEO) | Bought (not open market) | $880K |
| Mar 19, 2026 | Sanjay Chanda (C-suite exec) | Sold (not open market) | $828K |
| Mar 19, 2026 | Joshua M Eizen (Insider) | Sold (not open market) | $717K |
| Mar 19, 2026 | Joseph S Zakrzewski (Insider) | Sold (not open market) | $660K |
| Mar 19, 2026 | Lucy Day (CFO) | Sold (not open market) | $486K |
| Mar 19, 2026 | Joseph S Zakrzewski (Insider) | Bought (not open market) | $391K |
| Mar 19, 2026 | Joshua M Eizen (Insider) | Bought (not open market) | $360K |
| Mar 19, 2026 | Kabeer Aziz (Insider) | Sold (not open market) | $358K |
| Mar 19, 2026 | Robin Shane Readnour (Insider) | Sold (not open market) | $358K |
| Mar 19, 2026 | Lucy Day (CFO) | Bought (not open market) | $322K |
| Mar 19, 2026 | Lucy Day (CFO) | Bought (not open market) | $288K |
| Mar 19, 2026 | Sanjay Chanda (C-suite exec) | Sold (not open market) | $275K |
Who's trading ANTX
- Sarah Joanne Williams, Insider: sold $1.5K (2 sales), last May 29, 2026
- Kabeer Aziz, Insider: other filings, last Apr 10, 2026
- Gilbert Lynn Marks, Insider: other filings, last Apr 10, 2026
- Patricia A. Martin, Insider: other filings, last Apr 10, 2026
- Joseph S Zakrzewski, Insider: other filings, last Mar 19, 2026
- Joshua M Eizen, Insider: sold $28.2K (3 sales), last Mar 19, 2026
- Margaret M FitzPatrick, Insider: other filings, last Mar 19, 2026
- Stephanie Wong, Insider: other filings, last Mar 19, 2026
- Melvin K Spigelman, Insider: other filings, last Mar 19, 2026
- Sanjay Chanda, C-suite exec: sold $9.3K (2 sales), last Mar 19, 2026
- Lucy Day, CFO: sold $8.9K (2 sales), last Mar 19, 2026
- Eric Easom, CEO: other filings, last Mar 19, 2026
- Robin Shane Readnour, Insider: other filings, last Mar 19, 2026
- Stephen David Prior, C-suite exec: sold $7.4K (3 sales), last Jan 6, 2026
Get free alerts when an insider at AN2 Therapeutics, Inc files a new trade →